Cancer Chemotherapy and Pharmacology

, Volume 74, Issue 2, pp 333–340 | Cite as

Frontline treatment with gemcitabine, oxaliplatin and erlotinib for the treatment of advanced or metastatic pancreatic cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG)

  • O. Katopodis
  • J. Souglakos
  • E. Stathopoulos
  • A. Christopoulou
  • E. Kontopodis
  • A. Kotsakis
  • K. Kalbakis
  • N. Kentepozidis
  • A. Polyzos
  • D. Hatzidaki
  • V. Georgoulias
Original Article



Intravenous gemcitabine is the standard of care for patients with metastatic cancer of the pancreas. Gemcitabine-based chemotherapy combinations, either doublets or triplets, have been tested in the past but have offered a small advantage (Brodoefel et al. in Eur J Radiol 73:594–600, 2010). In the present study, we present the results of the triplet gemcitabine–oxaliplatin–erlotinib combination as firstline treatment in this setting.

Patients and methods

Seventy-one eligible patients were included in this study. All patients received chemotherapy with gemcitabine (1,100 mg/m2 on days 1 and 8) plus oxaliplatin (130 mg/m2 on day 8) and erlotinib (100 mg p.o./day for 21 days). The treatment cycle was 21 days.


Partial response was achieved in 15 patients (21 %; 95 % CI 11.63–30.62) and stable disease in 15 patients (21 %). Forty-one patients (57.8 %) experienced disease progression. Median progression-free survival was 5.2 months (range 0.6–34.7; 95 % CI 3.71–6.76). The median overall survival was 10.5 months (95 % CI 7.39–13.61) and the 1-year survival estimate 47.3 %. The main adverse events were grade 3/4 anemia occurring in three (4.2 %) patients and grade 3 and 4 thrombocytopenia occurring in eight (11.3 %) and three (4.2 %) patients, respectively. Grade 4 neutropenia was rare (1.4 %), and one patient presented febrile neutropenia.


This study demonstrated that the combination of gemcitabine, oxaliplatin and erlotinib is active, well tolerated and safe for patients with metastatic adenocarcinoma of the pancreas. However, the results do not seem to be better than those reported with chemotherapy alone.


Gemcitabine Oxaliplatin Erlotinib Phase II trial Pancreas 



This work was partially supported by a research Grant from the Cretan Association for Biomedical Research (CABR). Dr E. K. was a recipient of a CABR clinical fellowship.

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Brodoefel H, Bethge W, Vogel M et al (2010) Early and late-onset acute GvHD following hematopoietic cell transplantation: CT features of gastrointestinal involvement with clinical and pathological correlation. Eur J Radiol 73:594–600PubMedCrossRefGoogle Scholar
  2. 2.
    Malvezzi M, Bertuccio P, Levi F et al (2014) European cancer mortality predictions for the year 2014. Ann Oncol. doi: 10.1093/annonc/mdu138
  3. 3.
    Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24:2137–2150PubMedCrossRefGoogle Scholar
  4. 4.
    Goulart BH, Clark JW, Lauwers GY et al (2009) Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis. J Hematol Oncol 2:13PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Burris HA III, Moore MJ, Andersen J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–2413PubMedGoogle Scholar
  6. 6.
    Moore MJ, Goldstein D, Hamm J et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960–1966PubMedCrossRefGoogle Scholar
  7. 7.
    Bria E, Milella M, Gelibter A et al (2007) Gemcitabine-based combinations for inoperable pancreatic cancer: have we made real progress? A meta-analysis of 20 phase III trials. Cancer 110:525–533PubMedCrossRefGoogle Scholar
  8. 8.
    Cunningham D, Chau I, Stocken DD et al (2009) Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 27:5513–5518PubMedCrossRefGoogle Scholar
  9. 9.
    Heinemann V, Boeck S, Hinke A et al (2008) Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 8:82PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Poplin E, Feng Y, Berlin J et al (2009) Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 27:3778–3785PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Kindler H, Niedzwiecki D, Hollis D et al (2007) A double-blind, placebo-controlled, randomised phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in pts with advanced pancreatic cancer (PC): a preliminary analysis of Cancer and Leukemia Group B (CALGB) 80303. J Clin Oncol 25:18S (Abstact 4508)Google Scholar
  12. 12.
    Philip P, Benedetti J, Fenoglio-Preiser C et al (2007) Phase III study of gemcitabine (G) plus cetuximab (C) versus gemcitabine in patients (pts) with locally advanced or metastatic pancreatic adenocarcinoma (PC): SWOG S0205 study. J Clin Oncol 25:18S (Abstract LBA4509)Google Scholar
  13. 13.
    Louvet C, Labianca R, Hammel P et al (2005) Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23:3509–3516PubMedCrossRefGoogle Scholar
  14. 14.
    Herbst RS (2005) Erlotinib. Clin Adv Hematol Oncol 3:125–141PubMedGoogle Scholar
  15. 15.
    Patt YZ, Baron AD, Parks VA et al (2010) Phase II trial of gemcitabine (G), oxaliplatin (O), and erlotinib (T) for the treatment of hepatocellular carcinoma (HCC) and biliary tree cancers (BTC). J Clin Oncol 28:15s (Abstract 4153)Google Scholar
  16. 16.
    Mavroudis D, Pappas P, Kouroussis C et al (2003) A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors. Ann Oncol 14:304–312PubMedCrossRefGoogle Scholar
  17. 17.
    National Cancer Institute (2012) Common toxicity criteria for adverse events, version 2.0. National Cancer Institute, Bethesda.
  18. 18.
    Gutierrez J, Williams EJ, O’Donovan J et al (2011) Monitoring clinical outcomes, pathological changes and shedding of Chlamydophila abortus following experimental challenge of periparturient ewes utilizing the natural route of infection. Vet Microbiol 147:119–126PubMedCrossRefGoogle Scholar
  19. 19.
    Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247PubMedCrossRefGoogle Scholar
  20. 20.
    Von Hoff DD, Ervin T, Arena FP et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369:1691–1703CrossRefGoogle Scholar
  21. 21.
    Hu J, Zhao G, Wang HX et al (2011) A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma. J Hematol Oncol 26:4–11Google Scholar
  22. 22.
    Lee J, Park SH, Chang HM et al (2012) Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 13:181–188PubMedCrossRefGoogle Scholar
  23. 23.
    American Cancer Society (2014) Cancer facts & figures 2014. American Cancer Society, AtlandaGoogle Scholar
  24. 24.
    Tempero MA, Berlin J, Ducreux M et al (2011) Pancreatic cancer treatment and research: an international expert panel discussion. Ann Oncol 22:1500–1506PubMedCrossRefGoogle Scholar
  25. 25.
    Van Cutsem E, Vervenne WL, Bennouna J (2009) Rash as a marker for the efficacy of gemcitabine plus erlotinib-based therapy in pancreatic cancer: results from the AViTA study. J Clin Oncol 27:15S (Abstract 4532)Google Scholar
  26. 26.
    Moore MJ, da Cunha Santos G, Kamel-Reid S et al (2007) The relationship of K-ras mutations and EGFR gene copy number to outcome in patients treated with Erlotinib on National Cancer Institute of Canada Clinical Trials Group trial study PA.3. J Clin Oncol 25:18S (Abstract 4521)Google Scholar
  27. 27.
    Conroy T, Desseigne F, Ychou M et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Eng J Med 364:1817–1825CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • O. Katopodis
    • 1
  • J. Souglakos
    • 1
  • E. Stathopoulos
    • 1
  • A. Christopoulou
    • 1
  • E. Kontopodis
    • 1
  • A. Kotsakis
    • 1
  • K. Kalbakis
    • 1
  • N. Kentepozidis
    • 1
  • A. Polyzos
    • 1
  • D. Hatzidaki
    • 1
  • V. Georgoulias
    • 1
  1. 1.Hellenic Oncology Research Group (HORG)AthensGreece

Personalised recommendations